Elicitation of both CD4+ and CD8+ T-cell-mediated specific immune responses to HCA587 protein by autologous dendritic cells

Scandinavian Journal of Immunology

Volumn 60, Issue 5, 2004, Pages 506-513

  Li, B ^a   He, X ^a   Pang, X ^a   Zhang, H ^a   Chen, J ^a   Chen, W ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HCA587 ANTIGEN; INTERLEUKIN 4; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOLOGY; CYTOKINE RELEASE; DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VACCINE PRODUCTION;

ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; LIVER NEOPLASMS; NEOPLASM PROTEINS; STAINING AND LABELING;

EID: 8444248208     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01503.x     Document Type: Article

References (27)

1. Boon T, Old LJ. Cancer tumor antigens. Curr Opin Immunol 1997;9:681.
2. Thurner B, Haendle I, Roder C et al. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669.
3. Marchand M, van Baren N, Weynants P et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigen peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;18:219.
4. Wang Y, Han KJ, Pang XW et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol 2002;169:1102.
5. Lucas S, Plaen ED, Boon T. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: Four new members of the MAGE family with tumor-specific expression. Int J Cancer 2000;87:55.
6. Gure AO, Stockert E, Arden KC et al. CT10: a new CT antigen homologous to CT7 and the MAGE family, identified by representational difference analysis. Int J Cancer 2000;85:726.
7. Van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:l643.
8. Li B, Qian XP, Pang XW et al. HCA587 antigen expression in normal tissues and cancers: correlation with tumor differentiation in hepatocellular carcinoma. Lab Invest 2002;83:1185.
9. Butterfield LH, Ribas A. Immunotherapy of hepatocellular carcinoma. Expert Opin Biol 2002;2:123.
10. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997;186:1183.
11. Li B, Wu HY, Qian XP, Li Y, Chen WF. Expression, purification and serological analysis of hepatocellular carcinoma associated antigen HCA587 in insect cells. World J Gastroenterol 2003;9:678.
12. Romani N, Reider D, Heuer M et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996;196:137.
13. + T-cell response in a northern Chinese population. Tissue Antigens 2003;62:285.
14. + cytotoxic T lymphocytes correlates with increased intracellular perform expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Clin Cancer Res 2001;7:804s.
15. Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature 2001;4ll:380.
16. Jager E, Jager D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002;14:178.
17. Internati MC, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH. Sperm protein 17 (Spl7) is a suitable target for immunotherapy of multiple myeloma. Blood 2002;100:961.
18. Whiteside TL. Immunologic monitoring of clinical trials in patients with cancer: technology versus common sense. Immunol Invest 2000;29:149.
19. Schmittel A, Keilholz U, Thiel E, Scheibenbogen C. Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J Immunother 2000;23:289.
20. + T cells closely correlated with CD56 surface expression. J Immunol 2000;164:1148.
21. Kaufmann AM, Nieland J, Schinz M et al. HPV16 L1E7 chimeric virus-like panicles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 2001;92:285.
22. Michel N, Ohlschlager P, Osen W et al. T cell response against human papillomavirus (HPV) 16, E7 in mice: comparison of Cr- release assay, intracellular IFN-γ production, ELISPOT and tetramer staining. Intervirology 2002;45:290.
23. + T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-γ ELISPOT assay. Int J Cancer 2001;93:549.
24. Parish C. Cancer immunotherapy: The past, present and the future. Immunol Cell Biol 2003;81:106.
25. + T cell help. J Exp Med 1997;186:65.
26. Romani N. Human Th1 and Th2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 1992;98:279.
27. Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 2002;346:1752.